Free Trial

Promis Neurosciences (PMN) Competitors

Promis Neurosciences logo
$0.48 +0.02 (+3.92%)
Closing price 04:00 PM Eastern
Extended Trading
$0.48 0.00 (-0.21%)
As of 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

PMN vs. SPRO, ABOS, SCLX, TCRX, ZNTL, CGTX, EXOZ, ALXO, MGNX, and ADVM

Should you be buying Promis Neurosciences stock or one of its competitors? The main competitors of Promis Neurosciences include Spero Therapeutics (SPRO), Acumen Pharmaceuticals (ABOS), Scilex (SCLX), TScan Therapeutics (TCRX), Zentalis Pharmaceuticals (ZNTL), Cognition Therapeutics (CGTX), eXoZymes (EXOZ), ALX Oncology (ALXO), MacroGenics (MGNX), and Adverum Biotechnologies (ADVM). These companies are all part of the "pharmaceutical products" industry.

Promis Neurosciences vs. Its Competitors

Spero Therapeutics (NASDAQ:SPRO) and Promis Neurosciences (NASDAQ:PMN) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, profitability, earnings, media sentiment, valuation, analyst recommendations, risk and institutional ownership.

25.6% of Spero Therapeutics shares are held by institutional investors. Comparatively, 50.1% of Promis Neurosciences shares are held by institutional investors. 5.5% of Spero Therapeutics shares are held by insiders. Comparatively, 3.8% of Promis Neurosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Promis Neurosciences has lower revenue, but higher earnings than Spero Therapeutics. Spero Therapeutics is trading at a lower price-to-earnings ratio than Promis Neurosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Spero Therapeutics$47.98M2.92-$68.57M-$0.98-2.54
Promis NeurosciencesN/AN/A$2.78M-$0.21-2.27

In the previous week, Spero Therapeutics had 2 more articles in the media than Promis Neurosciences. MarketBeat recorded 6 mentions for Spero Therapeutics and 4 mentions for Promis Neurosciences. Promis Neurosciences' average media sentiment score of 0.74 beat Spero Therapeutics' score of 0.42 indicating that Promis Neurosciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Spero Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Promis Neurosciences
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Spero Therapeutics has a beta of 1.47, meaning that its stock price is 47% more volatile than the S&P 500. Comparatively, Promis Neurosciences has a beta of -0.17, meaning that its stock price is 117% less volatile than the S&P 500.

Promis Neurosciences has a net margin of 0.00% compared to Spero Therapeutics' net margin of -110.35%. Spero Therapeutics' return on equity of -120.27% beat Promis Neurosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Spero Therapeutics-110.35% -120.27% -55.61%
Promis Neurosciences N/A -266.69%-131.59%

Spero Therapeutics presently has a consensus target price of $5.00, suggesting a potential upside of 100.80%. Promis Neurosciences has a consensus target price of $4.33, suggesting a potential upside of 808.46%. Given Promis Neurosciences' stronger consensus rating and higher possible upside, analysts clearly believe Promis Neurosciences is more favorable than Spero Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Spero Therapeutics
1 Sell rating(s)
3 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.17
Promis Neurosciences
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50

Summary

Promis Neurosciences beats Spero Therapeutics on 9 of the 15 factors compared between the two stocks.

Get Promis Neurosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for PMN and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PMN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PMN vs. The Competition

MetricPromis NeurosciencesMED IndustryMedical SectorNASDAQ Exchange
Market Cap$24.70M$3.37B$6.11B$10.46B
Dividend YieldN/A2.29%5.73%4.77%
P/E Ratio-2.2722.7785.3627.36
Price / SalesN/A485.21607.16135.99
Price / CashN/A46.7037.4661.86
Price / Book0.9510.5512.426.81
Net Income$2.78M-$52.58M$3.32B$276.80M
7 Day Performance-16.26%1.09%1.01%0.27%
1 Month Performance14.01%16.09%10.75%8.31%
1 Year Performance-54.13%18.41%76.20%35.60%

Promis Neurosciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PMN
Promis Neurosciences
3.3321 of 5 stars
$0.48
+3.9%
$4.33
+808.5%
-54.1%$24.70MN/A-2.275Gap Up
SPRO
Spero Therapeutics
4.2787 of 5 stars
$2.16
+3.3%
$5.00
+131.5%
+91.9%$117.61M$47.98M-2.20150News Coverage
Analyst Downgrade
High Trading Volume
ABOS
Acumen Pharmaceuticals
3.2475 of 5 stars
$1.88
-3.1%
$7.00
+272.3%
-0.9%$117.51MN/A-0.8220News Coverage
Analyst Forecast
SCLX
Scilex
2.2368 of 5 stars
$18.23
+8.4%
$455.00
+2,395.9%
-47.1%$117M$56.59M-0.6380
TCRX
TScan Therapeutics
2.6186 of 5 stars
$1.97
-3.9%
$7.80
+295.9%
-62.0%$116.33M$2.82M-1.81100
ZNTL
Zentalis Pharmaceuticals
1.7286 of 5 stars
$1.55
-2.5%
$5.84
+276.8%
-48.0%$114.69M$67.43M-0.69160
CGTX
Cognition Therapeutics
2.594 of 5 stars
$1.75
+13.6%
$2.83
+61.9%
+308.1%$113.23MN/A-2.6120
EXOZ
eXoZymes
0.9098 of 5 stars
$13.50
+1.5%
N/AN/A$113.23M$70K0.0029
ALXO
ALX Oncology
3.9673 of 5 stars
$1.83
-13.3%
$3.30
+80.3%
+9.7%$112.99MN/A-0.8340Gap Up
MGNX
MacroGenics
4.4275 of 5 stars
$1.72
-2.3%
$3.60
+109.3%
-62.4%$111.24M$149.96M-3.02430
ADVM
Adverum Biotechnologies
3.7963 of 5 stars
$4.94
-6.8%
$19.75
+299.8%
-40.6%$111.22M$1M-0.63190

Related Companies and Tools


This page (NASDAQ:PMN) was last updated on 10/15/2025 by MarketBeat.com Staff
From Our Partners